A Phase 1/1b dose-escalation trial evaluating CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, in subjects with relapsed/refractory T-cell lymphoma Meeting Abstract
| Authors: | Mobasher, M.; Miller, R. A.; Janc, J. W.; Kwei, L.; Buggy, J. J.; Luciano, G.; Mohammady, A.; Kim, W. S.; Kim, Y. H.; Khodadoust, M. S.; Horwitz, S. M.; Radeski, D. |
| Abstract Title: | A Phase 1/1b dose-escalation trial evaluating CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, in subjects with relapsed/refractory T-cell lymphoma |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164602053 |
| DOI: | 10.1182/blood-2019-124958 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4030 -- Source: Wos |
